Navigation Links
HIV Drug Tenofovir Safe During Pregnancy, Study Suggests
Date:5/3/2012

THURSDAY, May 3 (HealthDay News) -- The use of the anti-HIV drug tenofovir during pregnancy appears to be safe for infants, new research suggests.

In combination with other anti-HIV drugs, tenofovir (Viread) is the first line of treatment for adults with HIV, the virus that causes AIDS. These findings should reassure pregnant women who are taking tenofovir, the researchers said.

The study was conducted by the U.S. National Institutes of Health network because previous studies showed that laboratory animals exposed to tenofovir in the womb were smaller at birth than those that were not exposed to the drug.

The new study included 2,000 infants born to HIV-positive mothers between 2003 and 2010 in the United States. Infants born to mothers who took tenofovir during pregnancy did not weigh less at birth and did not have shorter length than those born to women who did not take the drug.

At 1 year of age, however, children born to mothers who took tenofovir during pregnancy were slightly shorter and had slightly smaller head circumference (an average of about 1 centimeter) than children whose mothers did not take the drug, the investigators found.

The researchers said further studies should be conducted to follow the children as they grow and develop in order to identify any potential long-term effects of taking tenofovir during pregnancy.

The study was released online April 26 in advance of publication in an upcoming print issue of the journal AIDS.

"This study produced reassuring information regarding the use of tenofovir," first author Dr. George Siberry, of the Pediatric, Adolescent and Maternal AIDS Branch of the U.S. National Institute of Child Health and Human Development, said in a National Institutes of Health news release.

"Although further research is needed ... our findings favor the use of tenofovir in pregnancy to ensure good outcomes in the mother and prevent transmission of HIV to the infant," Siberry added.

More information

The New Mexico AIDS Education and Training Center has more about HIV and pregnancy.

-- Robert Preidt

SOURCE: U.S. National Institute of Child Health and Human Development, news release, May 1, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Tenofovir gel dropped from HIV prevention trial in women because it was not effective
2. Major HIV prevention trial in women to drop oral tenofovir arm
3. Next steps for Tenofovir gel: CONRAD and TIA sign license agreement
4. Study comparing tenofovir gel and oral tablet finds gel provides more drug to tissue
5. Tenofovir gel provides high level of protection against HIV in rectal tissue
6. Promising HIV prevention microbicide tenofovir gel being tested for safety of rectal use
7. Heroin Addicts Have Higher Pain Sensitivity, Even During Treatment
8. Presidential Recognition Awards presented during the 2012 AIUM Annual Convention
9. Exercise improves quality of life during breast cancer treatment
10. Few young women with cancer take steps to preserve fertility during treatments
11. Use of anesthesia providers during GI procedures is growing, but may be unnecessary
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
HIV Drug Tenofovir Safe During Pregnancy, Study Suggests
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations to ... Elite division on February 12th. Ms. Esparza qualified into this prestigious status ... competition held in Las Vegas, Nevada. Frida is one of approximately 25 gymnasts ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most award-winning ... Gran Fondo of Marin. For the second year in a row, cyclists will ... , “We are thrilled to provide our safe, non-toxic sunscreen to over 2,000 ...
(Date:2/23/2017)... ... ... The 89th Academy Awards will be celebrated this weekend, which means it’s ... Award. We invite you to enjoy our 11th annual tongue-in-cheek “salute” to the shoddiest ... for American Progress (CAP), for its report, Lessons From State Performance on NAEP: Why ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... a clinician-based audience, will be participating in Rare Disease Day events, hosted by ... In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, will ...
(Date:2/23/2017)... ... , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. will be ... Hot,” which will begin airing on February 24, 2017. The show chronicles the weight ... reality television series, “Here Comes Honey Boo Boo.” The earlier series from TLC lasted ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 24, 2017 Research and Markets has announced the ... Industry Forecast to 2025" report to their offering. ... The Global Empty Capsules Market is poised ... to reach approximately $2.9 billion by 2025. This industry ... on global as well as regional levels presented in the research scope. ...
(Date:2/24/2017)... HARRISBURG, Pa. , Feb. 24, 2017 ... Secretary of Drug and Alcohol Programs Jennifer Smith ... role in providing training for and using naloxone, a ... Mark McCullough , a recovery specialist and overdose ... naloxone by EMS providers. "A significant part ...
(Date:2/24/2017)... Juan Monteverde , founder and managing ... boutique securities firm headquartered at the Empire State Building ... that a class action lawsuit has been filed in the ... Inotek Pharmaceuticals Corporation (NASDAQ:  ITEK)("Inotek" or the "Company") on ... 2015 and December 30, 2016, inclusive (the "Class Period").  ...
Breaking Medicine Technology: